Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

514.93
+0.37000.07%
Volume:35.24K
Turnover:18.31M
Market Cap:130.65B
PE:29.97
High:522.10
Open:522.10
Low:514.47
Close:514.56
52wk High:560.25
52wk Low:374.17
Shares:253.72M
Float Shares:253.72M
Volume Ratio:0.85
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):17.18
EPS(LYR):15.32
ROE:23.54%
ROA:11.93%
PB:6.45
PE(LYR):33.61

Loading ...

Morgan Stanley's Analysis of Vertex's Major Acquisition of Crinetics: Enhancing Endocrine Portfolio and Unlocking Growth Potential

Stock News
·
Jul 08

Crinetics downgraded to In Line from Outperform at Evercore ISI

TIPRANKS
·
Jul 08

Vertex (VERX) Could Be 28% Undervalued As TD Cowen Backs Its Profit Plan

Simply Wall St.
·
Jul 08

Press Release: Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Dow Jones
·
Jul 08

Vertex to Report Q2 2026 Results After Market Close, Host Earnings Call

Reuters
·
Jul 08

Under the Radar: Vera Stock Jumps as Kidney-disease Drug Approved by FDA

Dow Jones
·
Jul 08

Intel, Micron, Spacex, GE Vernova, Caterpillar, and More Stocks That Explain Today's Market

Dow Jones
·
Jul 08

Top Midday Gainers

MT Newswires Live
·
Jul 08

Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says

MT Newswires Live
·
Jul 08

Sector Update: Healthcare

MT Newswires Live
·
Jul 08

Crinetics downgraded to Market Perform from Outperform at Citizens

TIPRANKS
·
Jul 08

Top Midday Stories: Amazon Seeking at Least $25 Billion From US Bond Sale; Fiserv Explores Sale of STAR Debit Network

MT Newswires Live
·
Jul 07

Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal

TIPRANKS
·
Jul 07

Cantor Sees 'clear Strategic Rationale' Behind Vertex's Buy of Crinetics

Dow Jones
·
Jul 07

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets

Benzinga
·
Jul 07

This Biotech Stock is Soaring 99% After Vertex Agrees to Takeover Deal

Dow Jones
·
Jul 07

Citi Remains a Buy on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 07

Vertex Pharmaceuticals is Maintained at Underperform by Baird

Dow Jones
·
Jul 07

Baird Adjusts Price Target on Vertex Pharmaceuticals to $350 From $330

MT Newswires Live
·
Jul 07

Major Deals Involving US Drugmakers and Biotechs over the Past Decade

Reuters
·
Jul 07